Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Outperform at Raymond James Financial

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities researchers at Raymond James Financial from a “market perform” rating to an “outperform” rating in a report released on Wednesday,Benzinga reports. The firm currently has a $10.00 target price on the stock. Raymond James Financial’s price objective suggests a potential upside of 222.58% from the company’s current price.

Several other equities analysts have also issued reports on the stock. BTIG Research reissued a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a report on Tuesday. HC Wainwright began coverage on Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. Wall Street Zen downgraded Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. Finally, UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tvardi Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.17.

Tvardi Therapeutics Trading Up 54.2%

Shares of Tvardi Therapeutics stock opened at $3.10 on Wednesday. The stock’s fifty day moving average price is $3.05 and its 200-day moving average price is $3.52. The firm has a market cap of $29.08 million, a P/E ratio of -1.00 and a beta of 0.39. Tvardi Therapeutics has a 12 month low of $1.50 and a 12 month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). Analysts forecast that Tvardi Therapeutics will post -2.39 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TVRD. Vanguard Group Inc. boosted its holdings in shares of Tvardi Therapeutics by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock valued at $16,335,000 after acquiring an additional 20,757 shares during the last quarter. American Financial Group Inc. acquired a new position in Tvardi Therapeutics during the fourth quarter valued at $962,000. Vestal Point Capital LP acquired a new stake in Tvardi Therapeutics during the 3rd quarter worth about $6,508,000. Geode Capital Management LLC raised its stake in shares of Tvardi Therapeutics by 6.2% during the 4th quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock valued at $676,000 after buying an additional 9,214 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Tvardi Therapeutics by 83.7% in the 4th quarter. State Street Corp now owns 115,501 shares of the company’s stock valued at $497,000 after buying an additional 52,637 shares during the period. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.